In Brief: In vivo radiopharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
In vivo radiopharmaceuticals: FDA will hold a public meeting Feb. 27 on developing regulations on the use of in vivo radiopharmaceuticals diagnosis and monitoring. The agency will be soliciting input from patient advocacy groups, physicians, industry and the public concerning the development of new regulations for the review of radiopharmaceutical applications as required by the FDA Modernization Act. Written comments are due March 4. The meeting will begin at 8:00 a.m. in Conference Rooms D and E of FDA's Parklawn building in Rockville, Maryland...